Procedural characteristics
| Characteristics | TT | AC+AT | DAT | p Value | Total |
| AC+ASA+CL | AC+ASA/CL | ASA+CL | |||
| (n = 278) | (n = 46) | (n = 81) | (n = 405) | ||
| Stents implanted, mean (SD) | 1.47 (0.73) | 1.54 (0.78) | 1.47 (0.87) | 0.082 | 1.48 (0.77) |
| Type of stent implanted | |||||
| BMS | 144 (51.8) | 33 (71.7) | 41 (50.6) | 0.039 | 218 (53.8) |
| DES | 134 (48.2) | 13 (28.3) | 40 (49.4) | 187 (46.2) | |
| Arterial access site | |||||
| Femoral sheath | 215 (77.3) | 35 (76.1) | 64 (79.0) | 0.92 | 314 (77.5) |
| Radial sheath | 63 (22.7) | 11 (23.9) | 17 (21.0) | 91 (22.5) | |
| Use of access-site closure devices | 39 (14.0) | 20 (43.5) | 32 (39.5) | <0.001* | 91 (22.5) |
| INR on the day of PCI, mean (SD) | 2.21 (0.84) | 1.89 (0.40) | 1.52 (0.50) | <0.001* | 2.04 (0.79) |
| Glycoprotein IIb/IIIa inhibitor | 27 (9.7) | 4 (8.7) | 9 (11.1) | 0.072 | 40 (9.9) |
Results are shown as No (%) unless stated otherwise.
*Statistically significant at 0.05 level after sequential Bonferroni correction.
ASA, acetylsalicylic acid (aspirin); AC+AT, any anticoagulant plus a single antiplatelet agent; BMS, bare metal stent; DAT, double antiplatelet therapy—aspirin plus clopidogrel; DES, drug-eluting stent; INR, international normalised ratio; PCI, percutaneous coronary intervention; TT, triple therapy—any anticoagulant plus aspirin plus clopidogrel.